NFE2L2 and non-small cell lung carcinoma: For NSCLC patients whose tumors harbor mutations in EGFR, disruption of the KEAP1/NRF2 pathway is of the most recently reported mechanisms by which EGFR-tyrosine kinase inhibitors (EGFR-TKI) resistance occurs [5].